Anti-Human HLA-DP Monomorphic – Purified In vivo GOLD™ Functional Grade

Pricing & Details

Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
HLA-DP Monomorphic
Prod No.
Add to cart
H260-1.0 mg
1.0 mg
In stock
H260-5.0 mg
5.0 mg
In stock
H260-25 mg
25 mg
In stock
H260-50 mg
50 mg
In stock
H260-100 mg
100 mg
In stock

Antibody Details

Matched Isotype Control
Mouse IgG3
Reactivity Species
Host Species
Product Concentration
≥ 2.0 mg/ml
1.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
>95% by SDS-PAGE and HPLC
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Anti-Human HLA-DP recognizes a (Mr 26-34 kDa) class II major histocompatibility complex (MHC) antigen.1 The antibody recognizes a monomorphic determinant present on cells expressing DP1, DP2, DP3, DP4 and DP5.
Antigen Distribution
The HLA-DP antigen is present on approximately 10% of normal peripheral blood lymphocytes but not on resting peripheral T-lymphocytes. HLA-DP is present in low density on peripheral blood monocytes and mitogen-stimulated T-lymphoblasts. Anti-HLA-DP reacts with most B-cell lines.

Antigen Details

HLA-DP Monomorphic

References & Citations

1. Bellone, CJ. et al. (1996) J Clin Invest. 97(10):2324-31. PubMed
2. Kasper, DL. et al. (2002) J Immunol.169(11):6149-53. Article Link
3. Lokhorst, HM et al. (2003) Clin Exp Immunol 131:340–346PubMed
4. Bloem, AC (2005) Br J Haematol.128(1):73-81.PubMed
5. Wright, TM et al. (1995) J Clin Invest. 96(1):586-96. PubMed
6. Nishikawa, Takeji et al. (2000) Journal of Investigative Dermatology 114(1): 88-94. PubMed
7. Wright, TM et al. (2001) Arthritis Rheum. 44(7):1654-9. PubMed
8. Lampson, L. A. et al. (1980) J. Immunol. 125:393
9. Yu, D. T. Y. et al. (1980) J. Exp. Med. 151:91
10. Warnke, R. et al. (1980) N. Eng. J. Med. 303:293
11. Wilkinson, KA et al. (2005) Infect Immun. 74(5):2991-8
General Western Blot Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.